BI Asset Management Fondsmaeglerselskab A S Sells 138,440 Shares of CVS Health Corporation $CVS

BI Asset Management Fondsmaeglerselskab A S lowered its position in shares of CVS Health Corporation (NYSE:CVS) by 37.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 234,859 shares of the pharmacy operator’s stock after selling 138,440 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in CVS Health were worth $15,352,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new stake in shares of CVS Health in the fourth quarter worth about $26,000. Sankala Group LLC purchased a new position in CVS Health during the 4th quarter valued at about $28,000. Mcguire Capital Advisors Inc. bought a new position in CVS Health during the 4th quarter valued at approximately $28,000. Finally, Ares Financial Consulting LLC bought a new position in CVS Health during the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 0.1%

CVS opened at $98.26 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $102.77. The stock has a market cap of $125.38 billion, a PE ratio of 43.29, a PEG ratio of 0.96 and a beta of 0.62. The business has a 50 day moving average of $89.31 and a 200-day moving average of $81.48.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

CVS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Morgan Stanley upped their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Royal Bank Of Canada raised their price target on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. UBS Group boosted their price objective on shares of CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Finally, Barclays raised their target price on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.